Limsrichamrern S, Chanapul C, Mahawithitwong P, Sirivatanauksorn Y, Kositamongkol P, Asavakarn S, Tovikkai C, Dumronggittigule W
Hepatopancreatobiliary and Transplant Surgery Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Hepatopancreatobiliary and Transplant Surgery Unit, Division of General Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Transplant Proc. 2016 May;48(4):1176-8. doi: 10.1016/j.transproceed.2015.12.096.
Tacrolimus is the most widely used immunosuppressive drug after liver transplantation. Whole blood tacrolimus level is used for drug monitoring. Because of strong uptake by erythrocytes (95% to 98%), hematocrit level is an important factor for evaluation whole blood tacrolimus level. There has been no formula to calculate the effect of hematocrit on the whole blood tacrolimus level. The aim of this study is to evaluate the effect of hematocrit on the whole blood tacrolimus level.
Twenty-five patients were included in this study. Blood samples during routine follow-up were used. All patients received tacrolimus for more than 30 days after liver transplantation. Approximately half of the plasma was removed. Blood samples were remixed and remeasured for hematocrit and whole blood tacrolimus levels. Pearson correlation and linear regression were performed to generate a formula for corrected tacrolimus level.
Thirteen male and 12 female patients participated in this study. There was a significant positive correlation between hematocrit ratio and tacrolimus ratio (r = 0.765, r(2) = 0.585, P < .001). The pattern of linear relationship between hematocrit ratio and tacrolimus ratio is defined by the regression equation, and the formula to correct tacrolimus level at hematocrit 40% is as follows: [Formula: see text]
Hematocrit has a significant effect on tacrolimus level. Better dose adjustment for patients should include the consideration of hematocrit levels. Further studies are required to validate this formula and clinical significance.
他克莫司是肝移植后使用最广泛的免疫抑制药物。全血他克莫司水平用于药物监测。由于红细胞对其摄取能力强(95%至98%),血细胞比容水平是评估全血他克莫司水平的重要因素。目前尚无计算血细胞比容对全血他克莫司水平影响的公式。本研究旨在评估血细胞比容对全血他克莫司水平的影响。
本研究纳入25例患者。使用常规随访期间的血样。所有患者在肝移植后接受他克莫司治疗超过30天。去除约一半血浆。将血样重新混合并重新测量血细胞比容和全血他克莫司水平。进行Pearson相关性分析和线性回归以生成校正他克莫司水平的公式。
13例男性和12例女性患者参与本研究。血细胞比容比值与他克莫司比值之间存在显著正相关(r = 0.765,r² = 0.585,P <.001)。血细胞比容比值与他克莫司比值之间的线性关系模式由回归方程定义,血细胞比容为40%时校正他克莫司水平的公式如下:[公式:见正文]
血细胞比容对他克莫司水平有显著影响。对患者进行更好的剂量调整应考虑血细胞比容水平。需要进一步研究以验证该公式及其临床意义。